Scinai Immunotherapeutics (SCNI) Total Current Liabilities (2017 - 2026)

Scinai Immunotherapeutics has disclosed Total Current Liabilities across 10 years of filings, most recently posting $2.2 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 5.28% year-over-year to $2.2 million; the TTM figure through Jun 2026 stood at $2.2 million (up 5.28% YoY), while the FY2025 annual figure was $1.6 million, down 12.24% from the prior year.
• Total Current Liabilities came in at $2.2 million for Q2 2026 at Scinai Immunotherapeutics, down from $2.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $6.7 million in Q2 2022 to a low of $1.4 million in Q3 2024.
• Average Total Current Liabilities over 5 years is $2.2 million, with a median of $1.9 million recorded in 2023.
• Year-over-year, Total Current Liabilities sank 93.2% in 2022 and climbed 26.79% in 2025.
• Over 5 years, Total Current Liabilities stood at $2.3 million in 2022, then retreated by 23.87% to $1.8 million in 2023, then climbed by 1.46% to $1.8 million in 2024, then slipped by 12.24% to $1.6 million in 2025, then jumped by 40.82% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $2.2 million in Q2 2026, $2.7 million in Q1 2026, and $1.6 million in Q4 2025.